Lung Cancer Research Dream Team

Stand Up To Cancer

Ushers In New Approach to Research with Calls by AACR for SU2C Dream Teams on “Interception” of Pancreas and Lung Cancers, Each Funded at $7 Million

Stand Up To Cancer (SU2C) broke new ground today when the American Association for Cancer Research (AACR), its scientific partner, announced to the cancer research community funding to support new Dream Teams focused on “cancer interception” of the pancreas and lung.

“Interception is the new frontier in cancer research,” said Phillip A. Sharp, PhD, chairperson of the SU2C Scientific Advisory Committee, Institute Professor at the Massachusetts Institute of Technology and its Koch Institute for Integrative Cancer Research, and winner of the 1993 Nobel Prize in Physiology or Medicine. “Essentially, we want to find cancer at its very earliest stages and stop it before it becomes a problem for the patient.  This approach has not been a focus of any of the previous Dream Teams and could greatly benefit patients.”

“Cancer interception is the active way of combating cancer and carcinogenesis at earlier and earlier stages,” said Elizabeth Blackburn, PhD, president of the Salk Institute for Biological Studies, winner of the 2009 Nobel Prize in Physiology or Medicine, and author of a seminal 2011 article on cancer interception published in Cancer Prevention Research, an AACR journal. “Stand Up To Cancer is to be commended for encouraging research on this new approach.”

The AACR issued a separate Call for Ideas for each of the proposed teams:

• The SU2C-Lustgarten Foundation Pancreatic Cancer Interception Dream Team, which will provide up to $7 million over a four-year term to advance innovative approaches to intercept the disease-causing process.  The Lustgarten Foundation, based in Bethpage, N.Y., is the largest private funder in the U.S. of pancreatic cancer research.  The new team will be the fifth SU2C Team supported by the Lustgarten Foundation, bringing its total investment in SU2C research to $17,520,000.

• The SU2C-LUNGevity-American Lung Association Lung Cancer Interception Dream Team, which will provide up to $7 million to solve key problems in lung cancer interception research.  LUNGevity Foundation is the leading lung cancer-focused private funder of research in the United States, with a programmatic focus on early detection. The American Lung Association is the country’s leading organization working to improve lung health and prevent lung disease.  Specifically involved is LUNG FORCE, a Lung Association initiative that seeks to unite the nation in defeating lung cancer.

In addition, through a partnership with leading health care research and innovation collaborative OptumLabs, each team will have the ability to conduct research using OptumLabs’ proprietary database of de-identified claims and electronic health record data, analytic tools, and research support to pursue the proposed goals of the Dream Team.

Learn More